Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients with CML-CP: The ENRICH Study

Jorge E. Cortes, Jeffrey H. Lipton, Carole B. Miller, Lambert Busque, Luke P. Akard, Javier Pinilla-Ibarz, Christopher Keir, Ghulam Warsi, Felice P. Lin, Michael J. Mauro

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

Chronic treatment-related adverse events adversely affect quality of life, treatment adherence, and clinical outcomes of many patients taking imatinib. The ENRICH (Exploring Nilotinib to Reduce Imatinib Related Chronic Adverse Events) study evaluated the effect of switching 52 such patients to nilotinib. Within 3 months of switching, improvements in imatinib-related adverse events and quality of life and ongoing achievement and maintenance of molecular and cytogenetic responses were observed. Background Many patients with chronic myeloid leukemia in chronic phase experience chronic treatment-related adverse events (AEs) during imatinib therapy. These AEs can impair quality of life and lead to reduced treatment adherence, which is associated with poor clinical outcomes. Patients and Methods In the phase II ENRICH (Exploring Nilotinib to Reduce Imatinib Related Chronic Adverse Events) study (N = 52), the effect of switching patients with imatinib-related chronic low-grade nonhematologic AEs from imatinib to nilotinib was evaluated. Results Three months after switching to nilotinib, 84.6% of the patients had overall improvement in imatinib-related AEs (primary endpoint). Of 210 imatinib-related AEs identified at baseline, 62.9% had resolved within 3 months of switching to nilotinib. Of evaluable patients, most had improvements in overall quality of life after switching to nilotinib. At screening, 65.4% of evaluable patients had a major molecular response (BCR-ABL1 ≤ 0.1% on the International Scale). After switching to nilotinib, the rate of the major molecular response was 76.1% at 3 months and 87.8% at 12 months. Treatment-emergent AEs reported with nilotinib were typically grade 1 or 2; however, some patients developed more serious AEs, and 8 patients discontinued nilotinib because of new or worsening AEs. Conclusion Overall, results from the ENRICH study demonstrated that switching to nilotinib can mitigate imatinib-related chronic low-grade nonhematologic AEs in patients with chronic myeloid leukemia in chronic phase, in conjunction with acceptable safety and achievement of molecular responses.

Original languageEnglish (US)
Pages (from-to)286-296
Number of pages11
JournalClinical Lymphoma, Myeloma and Leukemia
Volume16
Issue number5
DOIs
StatePublished - May 1 2016
Externally publishedYes

Keywords

  • Chronic myeloid leukemia
  • Clinical trials
  • Imatinib-related chronic adverse events
  • Nilotinib
  • Switch

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients with CML-CP: The ENRICH Study'. Together they form a unique fingerprint.

  • Cite this